Correlates of Protection

提供: Vaccipedia | Resources for Vaccines, Tropical medicine and Travel medicine
2023年9月10日 (日) 15:47時点におけるVaccipedia.admin (トーク | 投稿記録)による版 (Vaccipedia.admin がページ「Correlates of Protection and interpretations of antibody titers」を「Correlates of Protection」に移動しました)
ナビゲーションに移動 検索に移動

Correlates of Protection

Definitions of terms
Correlates of Protection (CoP) An immune response statistically correlated with protection
Mechanistic CoP (mCoP) An immune response responsible for protection
Non-mechanistic CoP (nCoP) An immune response surrogating mCoP and easily measured

Identifying method of CoP (mCoP)

  • Theoretically
    • To measure immune responses at the time of exposure to the infection and compare them between those who get infection and not
      • might be feasible by detecting immune responses of bloods donated just before an outbreak
  • Practically
    • To measure immune responses after the vaccination and compare them between those who get infection and not
      • usually done in vaccine clinical trial phase 3
    • To measure immune responses at the time of challenging exposure of vaccinated volunteers
      • would be ethically approved only for milder and/or treatable infections such as seasonal influenza, cholera, dengue or cytomegalovirus
    • To extrapolate vaccinated animal challenge model
    • To extrapolate protective level of dosing of passive immunization (antibody treatment)

Be careful

  • "Immune reseponses" contain various kinds of immunological functions, thus a single immune biomarker cannot necessarily be CoP
    • Serum antibodies with multiple isotypes and multiple functions
    • Mucosal antibodies with multiple isotypes and multiple functions
    • Helper T cells
    • Killer T cells
    • Regulatory T cells
    • Natural killer cells
    • Phagocytes and antigen-presenting cells
    • etc.
  • Protection against infection is generally different from protection against disease
    • You should focus on which type of protection you expect
Protection against infection Protection against disease
Polio Infection is prevented by mucosal antibodies at nasopharynx and intestine (IgA + diffused IgG) Disease (paralysis) is prevented by serum antibodies before entering CNS via blood
Pneumococcus Infection (bacteremia) is prevented by 0.20-0.35 µg/mL (ELISA) of serum antibodies Disease (pneumonia, otitis media, nasopharynx carriage) is prevented by >10 times higher serum antibodies

An example of measles

Chen, R. T., Markowitz, L. E., Albrecht, P., Stewart, J. A., Mofenson, L. M., Preblud, S. R., & Orenstein, W. A. (1990). Measles Antibody: Reevaluation of Protective Titers. In The Journal of Infectious Diseases (Vol. 162). https://doi.org/10.1093/infdis/162.5.1036
Comparison between Cases and Non-cases; serologically confirmed
Pre-exposure PRN ≤120
(GMT)
Pre-exposure PRN >120
(GMT)
Cases 8 cases
(63)
0 case
Non-cases 1 non-case
(56)
71 non-cases
(1157)
*PRN = Plaque Reduction Neutralization
t test p<0.001
Comparison among serologically discarded Non-cases
Pre-exposure PRN
216-874
Pre-exposure PRN
≥1052
Post-exposure PRN
boosted†
7 non-cases 0 non-case
Post-exposure PRN
unchanged
4 non-cases 7 non-cases
†suggestive of subclinical infection
Fisher's exact test p<0.001
Comparison among serologically discarded Non-cases
Pre-exposure PRN
<1052
Pre-exposure PRN
≥1052
Non-cases with
≥1 symptom‡
26 non-cases 11 non-cases
Non-cases with
no symptom
11 non-cases 24 non-cases
‡suggestive of subclinical infection
χ2 test p<0.002
Comparison between Cases and Non-cases; serologically confirmed
Pre-exposure PRN
≤120
Pre-exposure PRN
121-1051
Pre-exposure PRN
≥1052
Cases with
no vaccine
1 unvaccinated case
Cases with
1 vaccine
7 unvaccinated case
Non-cases with
no vaccine
0 unvaccinated non-case 0 unvaccinated non-case
Non-cases with
1 vaccine
36 vaccinated non-cases 35 vaccinated non-cases
  • Single definitive cut-off of CoP is not commonly available and CoP is generally relative
    • Generally speaking, the higher a CoP biomarker is, the more highly the subject is protected from infection or disease
    • In other words, a certain proportion of subjects with a certain level of CoP biomarker can be protected from infection/disease
      • The proportion of protected subjects increases as the level of CoP biomarker rises